MedTrace Logo

Estimation and Prediction of Individual Benefit From Postoperative Adjuvant Transcatheter Arterial Chemoembolization For Patients With Hepatocellular Carcinoma

NCT07562763 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1005

Last updated 2026-05-01

No results posted yet for this study

Summary

Adjuvant transarterial chemoembolization (TACE) is widely adopted in China for resectable hepatocellular carcinoma (HCC), yet its efficacy remains inconsistent. We aimed to identify factors influencing individual patient benefit using causal machine learning. To this end, we retrospectively collected HCC patients with high risk factors for tumor recurrence from four centers of China, divided into the discovery cohort and the validation cohort . The primary endpoint was disease-free survival (DFS). The primary endpoint was overall survival (OS).Individual treatment effects (ITEs) were estimated within a causal machine learning framework. An ITE \< 0 was considered recommendation for adjuvant TACE , while ITE ≥ 0 indicated active surveillance. The model would be validated in the validation cohort. The contribution of each variable to ITE was assessed using the Shapley Additive Explanations (SHAP). An online calculator would be developed for future use by public.

Conditions

  • Hepatocellular Carcinoma (HCC)
  • Transarterial Chemoembolization
  • Adjuvant Therapy
  • Machine Learning
  • Treatment Effectiveness

Sponsors & Collaborators

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    collaborator OTHER

  • Sun Yat-Sen University Cancer Center

    collaborator OTHER

  • No.2 People's Hospital of Fuyang City

    collaborator UNKNOWN

  • Anhui Provincial Hospital

    lead OTHER_GOV

Principal Investigators

  • Lianxin Liu, Ph.D. · The First Affiliated Hospital of USTC

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07562763 on ClinicalTrials.gov